clinical trials

News

United's PAH drug clears phase 3 trial, setting up filings

United Therapeutics will file ralinepag as a treatment for pulmonary arterial hypertension later this year, but can it compete in a crowded market?

News

New FDA knockback hits uniQure and Huntington patients hard

uniQure looks like it may have to run another trial of its Huntington's disease gene therapy AMT-130, delaying the highly anticipated programme.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Elderly man talks to younger female nurse beside a Grail screening vehicle

Grail's multi-cancer test fluffs its lines in UK trial

Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.

United's PAH drug clears phase 3 trial, setting up filings

New FDA knockback hits uniQure and Huntington patients hard

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Lilly says orforglipron tops Novo pill in diabetes trial

Head-to-head trial dents Novo Nordisk's obesity hopes

Grail's multi-cancer test fluffs its lines in UK trial

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks